Core Viewpoint - Modern Dairy announced the acquisition of approximately 1.28% equity in China Shengmu for HKD 37.52 million, which will increase its shareholding to over 30%, triggering a mandatory offer to acquire the remaining shares at HKD 0.35 per share, with a total potential cost of approximately HKD 2.016 billion [1] Group 1: Acquisition Details - The acquisition will elevate Modern Dairy's and its concerted parties' (Mengniu) shareholding from 29.99% to over 30% [1] - Modern Dairy plans to acquire the remaining shares of China Shengmu at a price of HKD 0.35 per share, with a maximum total price of about HKD 2.016 billion [1] Group 2: Operational Impact - The combined annual raw milk production post-acquisition is expected to exceed 4 million tons, positioning the company among the top global livestock farming enterprises [1] - The scale advantage from the acquisition will enhance bargaining power in the procurement of bulk materials like feed, effectively reducing unit costs and solidifying cost leadership [1] Group 3: Product Line Enhancement - The proportion of specialty milk (including organic milk) in Modern Dairy's product mix is projected to increase from 8% to over 20% following the integration of China Shengmu, thereby strengthening its high-end product line [1]

Financial Data and Key Metrics Changes - The company reported strong organic sales growth of 9.5% compared to last year's 11.5% [3] - Adjusted EPS grew by 11.1% to $3.19, despite tariff headwinds and higher interest expenses [9][16] - Adjusted gross margin improved to 65%, a 50 basis point increase year-over-year [14] - Adjusted operating margin was 25.6%, up 90 basis points from the previous year [15] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology achieved organic sales growth of 8.4%, with U.S. growth at 9.4% [10] - Instruments saw U.S. organic sales growth of 11.5%, driven by Surgical Technologies [10] - Orthopaedics reported organic sales growth of 11.4%, with U.S. knee business growing 8.4% [13] - Vascular had U.S. organic sales growth of 13.4%, attributed to new product launches [11] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.6%, with double-digit growth in vascular, trauma, and extremities [4] - International organic sales growth was 6.3%, with strong contributions from South Korea, Japan, and emerging markets [4] - The company anticipates continued strength in procedural volumes through the end of the year [6] Company Strategy and Development Direction - The company plans to remain active in M&A, supported by a healthy deal pipeline and strong balance sheet [5] - Focus on expanding international markets and launching successful products from the U.S. [4] - The upcoming Investor Day will discuss long-term strategy and growth potential [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the health of procedure volumes and capital markets, indicating strong demand for products [20][21] - The company expects to achieve double-digit growth in the Medical segment despite supply chain disruptions [11][21] - Management is optimistic about maintaining organic growth momentum and margin expansion in 2025 [26] Other Important Information - The company completed two small acquisitions during the quarter to enhance its product offerings [4][57] - The tariff impact for the full year is estimated at approximately $200 million [15][85] Q&A Session Summary Question: Insights on procedure volumes and capital equipment market - Management noted that procedure volumes are healthy, with strong capital markets and cash purchases driving growth [20][21] Question: Guidance on sales and margins for the fourth quarter - Management indicated that while they expect operational margin improvements, tariffs will offset some margin expansion [23] Question: Maintaining organic growth momentum in 2025 - Management highlighted a sustainable growth trajectory, expecting continued strong performance across all business lines [26] Question: Update on Inari integration and international expansion - Management confirmed that Inari is on track for double-digit growth, with international expansion expected to gain momentum in the second half of next year [41][38] Question: Competitive dynamics in the ASC market - Management expressed confidence in leveraging their full portfolio as procedures move to ASCs, which is beneficial for the company [54] Question: Details on recent acquisitions - Management described the NP Seal product as a low-cost solution for wound treatment and the balloon product for fecal incontinence as a new addition to their offerings [57] Question: Pricing power and future expectations - Management believes they will maintain pricing power across all business lines, driven by product innovation and contracting strategies [80]

Financial Data and Key Metrics Changes - The company reported strong organic sales growth of 9.5% compared to the previous year's 11.5% [2][9] - Adjusted earnings per share (EPS) increased by 11.1% to $3.19, driven by strong sales growth and margin expansion [9][16] - Adjusted gross margin improved to 65%, a 50 basis point increase from the previous year, despite tariff headwinds [14][15] - Adjusted operating margin was 25.6%, which is 90 basis points favorable compared to the same quarter last year [15] Business Line Data and Key Metrics Changes - MedSurg and Neurotechnology experienced organic sales growth of 8.4%, with U.S. growth at 9.4% and international growth at 5.1% [10] - Orthopaedics had organic sales growth of 11.4%, with U.S. growth at 12.9% and international growth at 7.8% [12] - Vascular reported U.S. organic sales growth of 13.4%, driven by new product launches [11] - Neurocranial saw U.S. organic sales growth of 12.9%, supported by strong performance in various neurosurgical products [12] Market Data and Key Metrics Changes - U.S. organic sales growth was 10.6%, with double-digit growth in vascular, trauma, and extremities businesses [3] - International organic sales growth was 6.3%, with notable contributions from South Korea, Japan, and emerging markets [3] - The company anticipates continued strength in procedural volumes through the end of the year [5] Company Strategy and Development Direction - The company completed two small acquisitions to enhance its product offerings in Orthopaedic Instruments and Sage business [3][49] - The company plans to remain active in M&A, supported by a healthy deal pipeline and strong balance sheet [4] - The company is focused on margin expansion and expects to deliver a second consecutive year of 100 basis points of adjusted operating margin expansion [4] Management's Comments on Operating Environment and Future Outlook - Management noted that procedural volumes remained healthy and expected continued strength in the order book [5][20] - The company is optimistic about maintaining organic growth momentum, projecting 10% growth for 2025 [25] - Management acknowledged supply chain disruptions but still expects double-digit growth in the Medical segment [20][43] Other Important Information - The company raised its full-year 2025 guidance, expecting organic net sales growth of 9.8% to 10.2% and adjusted EPS in the range of $13.50 to $13.60 [16] - The upcoming Investor Day on November 13th will provide further insights into the company's long-term strategy [7][70] Q&A Session Summary Question: Insights on procedure volumes and capital equipment market - Management indicated that procedure volumes are healthy, with strong capital markets and hospital balance sheets supporting cash purchases [19][20] Question: Maintaining growth momentum and margin expansion - Management expressed confidence in sustaining organic growth and indicated that tariff impacts would offset some margin expansion in Q4 [24][23] Question: Competitive dynamics in orthopaedics - Management highlighted strong performance in the knee business and ongoing momentum from MEKO installations [30] Question: Update on Inari Medical integration and growth - Management reported positive progress in integrating Inari and expects double-digit growth in Q4 and Q1 next year [37][38] Question: Supply chain disruptions in the Medical segment - Management acknowledged ongoing supply chain issues but expects a strong rebound in Q4 [42][43] Question: Future pricing power in orthopaedics - Management believes there are opportunities for continued pricing power across all business lines [66] Question: Upcoming Investor Day and long-term targets - Management confirmed that long-term financial goals will be updated during the Investor Day [68][69]

Core Viewpoint - Wall Street analysts anticipate that the Trump administration will impose significant regulatory challenges for Comcast Corp (NASDAQ: CMCSA) if it moves forward with its reported plans to acquire WarnerMedia [1] Group 1: Regulatory Environment - Analysts expect the Trump administration to create substantial regulatory hurdles for Comcast in the event of the acquisition [1]

Group 1: L'Oréal and Armani Group - L'Oréal's CEO Nicolas Hieronimus expressed willingness to negotiate with Armani Group as per the late Mr. Armani's will [3] - The will stipulates that heirs must sell 15% of Armani Group's shares within 18 months and transfer an additional 30%-54.9% within 3-5 years to the same buyer [3] - L'Oréal recently acquired Kering Beauty for €4 billion and has sufficient cash reserves, indicating capability for independent or partnered investment in Armani [3] Group 2: Brownes Dairy - Brownes Dairy plans to seek buyers or investors next year, with the sale process already underway [5] - The company has garnered significant interest from potential investors and aims for an IPO in 2026 [5] - Brownes Dairy was previously put up for sale after a loan recovery by Mengniu, amounting to AUD 200 million (approximately RMB 92 million) [5] Group 3: Qingdao Beer - Qingdao Beer terminated its plan to acquire 100% of Jimo Yellow Wine due to unmet conditions in the share transfer agreement [7] - The acquisition was expected to enhance Qingdao Beer's market position and open new growth avenues [7] Group 4: KKR and Costa Coffee - KKR is among a few companies negotiating to acquire Costa Coffee from Coca-Cola [10] - Costa Coffee, the largest coffee chain in the UK, has seen a reduction in store numbers in China since its acquisition by Coca-Cola for £3.9 billion in 2018 [10] - KKR's expertise in the food supply chain and digital integration could enhance Costa's business model and cash flow if the acquisition proceeds [10] Group 5: Haidilao - Haidilao is set to open its first hamburger store, "Xiao Hai Ai Zha hiburger," in Hunan, indicating a shift towards expanding its product line [13] - The new store is an upgrade from an existing brand and aims to attract younger consumers with its hamburger offerings priced between RMB 28-39.9 [13] Group 6: 7-Eleven Japan - 7-Eleven Japan will launch hydrogen-roasted coffee in collaboration with UCC, using hydrogen as a heat source for roasting [17] - The new coffee product is priced at 149 yen (approximately RMB 7), slightly higher than regular hot coffee [17] - This initiative aims to enhance 7-Eleven's brand image and attract a more niche consumer base through an environmentally friendly narrative [17] Group 7: IKEA - IKEA's global retail sales fell by 1% in the 2025 fiscal year, marking the second consecutive year of decline [19] - Despite the sales drop, product sales and customer numbers increased by 3%, with 66 new sales points opened globally [19] - IKEA continues to implement a pricing strategy aimed at attracting more consumers amid intense market competition [19] Group 8: Moutai Group - Moutai Group announced a significant leadership change, appointing Chen Hua, the former head of Guizhou Energy Bureau, as the new chairman [22] - This marks the fourth leadership change in five years for the liquor giant, with expectations for Chen to drive expansion into new consumer segments [22] Group 9: Wahaha - Reports indicate that Zhu Lidan, a core executive at Wahaha, has left the company, with her office vacated [25] - This departure follows a leadership transition at Wahaha, where Zong Fuli took over, leading to the exit of several long-standing executives [25] - The loss of Zhu, known for her cost control expertise, may impact the company's operational efficiency and negotiation capabilities [25] Group 10: Alexander McQueen - Alexander McQueen announced a three-year strategic review, initiating a restructuring plan that includes cutting approximately 55 jobs, or 20% of its London headquarters staff [27] - The brand aims to simplify its international market structure to restore growth confidence [27] - The restructuring reflects a shift towards a more pragmatic approach for the luxury brand, known for its unique niche [27]

Boyd Group Services Investor Call Summary Company Overview - **Company**: Boyd Group Services Inc. - **Industry**: North American collision industry - **Market Position**: Third largest player in a $50 billion industry with over 1,000 locations and $3 billion in revenue for the trailing twelve months ended June 30, 2025 [4][5] Key Acquisition Announcement - **Acquisition Target**: Joe Hudson's Collision Center - **Purchase Price**: $1.3 billion - **Strategic Importance**: - Increases Boyd's location count by 25% to 1,273 locations - Enhances operational margins and solidifies Boyd's market position [4][7][11] Financial Performance Highlights - **Third Quarter 2025 Estimates**: - Expected revenue growth of approximately 5% year-over-year - Anticipated same store sales growth of 2% to 2.5% - Projected adjusted EBITDA margin improvement to 12.3% to 12.5%, an increase of approximately 170 basis points year-over-year - Expected adjusted EBITDA growth of 21% to 23% for the quarter [5][6] Market Trends and Drivers - **Used Car Prices**: Rise in used car prices and moderation in auto insurance premiums are driving industry volumes - **Repairable Claims Environment**: Improvement in the repairable claims environment has contributed to positive same store sales growth [6][10] Joe Hudson's Collision Center Overview - **Founded**: 1989 in Alabama - **Current Operations**: 258 locations across 18 states, primarily in the Southeast U.S. - **Growth Rate**: 20% compounded annual growth rate in location count since 2020, with $722 million in sales and an adjusted EBITDA margin of 8.7% [8][10][12] Strategic Rationale for Acquisition - **Market Position**: Solidifies Boyd's position in the North American market with a combined estimated revenue share of only 7.6% - **Synergies**: Expected synergies of $35 million to $45 million, with 50% targeted for completion in the near term [11][18][20] - **Operational Improvements**: Enhanced density in key markets will provide opportunities for margin expansion and improved customer service [10][13] Financing and Leverage - **Transaction Financing**: Combination of equity, debt securities, and bank facilities to maintain a strong balance sheet - **Leverage Ratio**: Expected net debt to adjusted EBITDA ratio to increase to 3.4 times at closing, with a plan to reduce it back to current levels by 2027 [17][18] Future Outlook - **Long-term Growth Strategy**: Boyd aims to leverage the acquisition to accelerate profitability and solidify its market position - **Ongoing Initiatives**: Continued execution of Project 360 and other operational strategies to enhance growth and shareholder value [21]

本文是这个栏目的第172期。如果你对本文提到的相关的交易线索感兴趣，希望接触这些潜在的交易对 手，或者如果你手中直接握有希望交易的资金或者资产，欢迎与我们联系。（邮箱：zcjy@36kr.com） 一、本月新增1、求购字节跳动公司老股份额（预期估值3400亿美元） 交易价格：预期估值3400亿美元 资产交易市场，信息瞬息万变，消息真假难辨，即使买卖双方花费大量的时间、精力，推动成交往往困 难重重。为了能够帮助买卖双方更快速链接市场信息和潜在交易对手，避免不必要的投入与浪费，我们 特地打造了这样一档栏目。 3、求购DJI公司老股份额（预期估值170-200亿美元左右） 交易价格：预期估值170-200亿美元左右 资产规模：约3000-5000万美元份额 交易方式：具体看是否承担管理费和carry 联系方式：zcjy@36kr.com 2、求购小红书公司老股份额（预期估值380亿美元左右） 交易价格：预期估值380亿美元左右 资产规模：约3000-5000万美元 交易方式：可以接受进结构，价格具体看是否承担管理费和carry 联系方式：zcjy@36kr.com 交易方式：要求可以人民币交易的结构 联系方式：zc ...

Merger Announcement - FirstSun Capital Bancorp announced a merger with First Foundation, which was disclosed in a joint press release [2] - The merger discussion will be a key focus during the conference call, alongside the third quarter earnings results [2] Financial Results - FirstSun Capital Bancorp released its third quarter earnings, with additional details expected from First Foundation on October 30 [2] - Both companies will address their financial performance during the call, providing insights into their respective earnings [2]

Core Viewpoint - The conference call serves as an investor update for Skyworks and Qorvo, focusing on their proposed transaction and future outlook [3][4]. Group 1: Company Overview - Skyworks and Qorvo are represented by their respective CEOs, Phil Brace and Bob Bruggeworth, during the investor update [2]. - The call is accessible via the investor relations sections of both companies' websites, indicating a commitment to transparency and investor engagement [2]. Group 2: Forward-Looking Statements - The management of Skyworks and Qorvo will discuss forward-looking statements regarding their views on the proposed transaction, highlighting the strategic importance of this merger [3]. - The discussion will include potential risks and uncertainties associated with the forward-looking statements, which are standard in such corporate communications [4].

香港交 易及結算 所有限公司 及香港聯 合交易所 有限公司（「聯交所」）對本公 佈 的 內容 概 不 負 責 ，對 其 準 確 性或 完 整 性 亦 不發 表 任 何 聲 明， 並 明 確 表示 概 不 就因 本 公 佈 全 部或 任 何 部 分內 容 而 產 生 或因 依 賴 該 等 內容 而 引 致 的任 何損失承擔任何責任。 JIN MI FANG GROUP HOLDINGS LIMITED 今 米 房 集 團 控 股 有 限 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：8300） 自願性公佈 GEM上市規則的涵義 收購目標公司52% 股權 本 公 佈 由 今 米 房 集 團 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 ， 統 稱 為 「本集團」）自願作出，旨在讓本公司股東（「股東」）及潛在投資者知悉本集團 的最新業務發展。 誠 如 本公 司 截 至 二 零二 五 年 三 月三 十 一 日 止 年度 的 年 報 所 披露 ， 本 集 團於 中華人民共和國（「中國」）從事（ 其中包括 ）酒品供應業務。其業務範圍包括 但 不 限於 優 質 酒 品 的品 牌 管 理 ...